Device Trial Radar · NCT07746843
The Efficacy and Safety Study of 2107 Injection in Subjects With Mild to Moderate Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Jun 30, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- BioRegen Biomedical (Changzhou) Co., LtdNot on our public-company list
- Sponsor type
- Industry
- First posted
- Aug 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This will be a 26-week, prospective, international, multi-center, randomized, active-controlled, double-blinded (to subject and Investigator) study in subjects with mild to moderate OA in the knees to assess safety and efficacy of 2107 Injection following a single intra-articular injection as compared to DUROLANE® (the active comparator). A total of 286 subjects from approximately 15 sites and at least three (3) countries will be enrolled and randomized at a 1:1 ratio into the 2107 Injection arm or DUROLANE® arm. One (1) target knee of each subject (only one \[1\] knee to be treated) will receive a single intra-articular dose of 3 mL of 2107 Injection (16 mg/mL HA, i.e. 48 mg per dose) or 3 mL of DUROLANE® (20 mg/mL HA, i.e. 60 mg per dose). Subjects will be followed for 26 weeks after the intra-articular injection for safety and efficacy assessments. The study will consist of six (6) visits (see Table 1. Schedule of Assessments). Subjects who withdraw from the study will have an early termination visit. The primary efficacy endpoint will be the mean change in the Western Ontario and McMaster Universities (WOMAC) Pain sub-score on 100-mm Visual Analog Scale (VAS) from baseline to 13 weeks after intra-articular injection. The secondary efficacy endpoints include the changes in WOMAC sub-score and total score, PGA/IGA, the percentage of subjects taking rescue medication, the level of swelling and tenderness of the target knee and the Outcome Measures in Rheumatology Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) responder rate. The safety endpoint includes systemic and local safety profile.
Conditions
- Mild Knee Osteoarthritis
- Moderate Knee Osteoarthritis
Interventions
2107 InjectionDevice
Single intra-articular injection of 2107 Injection for knee osteoarthritis.
DUROLANE®Device
Single intra-articular injection of DUROLANE for knee osteoarthritis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in WOMAC Pain sub-score (100-mm VAS) from baseline to Week 13Time frame: Baseline to Week 13
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
CenterMed Krakow Sp. z o.o.
Krakow, Lesser Poland Voivodeship, Poland
Corporació Sanitària Parc Taulí
Sabadell, Barcelona, Spain
NHS Greater Glasgow and Clyde
Glasgow, Scotland, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.